FDA OK for Luminex's cystic fibrosis test
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Luminex's xTAG Cystic Fibrosis 39 Kit v2. The test detects 39 genetic mutations which cause cystic fibrosis (CF), and is used to assess whether couples planning a pregnancy are carriers of these variants, and also to screen newborn children. More than 10 million Americans are asymptomatic carriers of a CF-causing mutation, according to the Cystic Fibrosis Foundation. The diagnostic is an updated version of Luminex's (Austin, Texas) xTAG Cystic Fibrosis Kit, which received FDA clearance in May 2005. CF is a chronic inherited disease that is caused by mutations in the CF transmembrance conductance regulator (CFTR) gene.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.